Halozyme Therapeutics, Inc. (NASDAQ:HALO) has announced the appointment of Jim Daly, as the latest addition to its board of directors. Mr. Daly has 30-years of experience under his belt, as a biopharmaceutical executive. The CEO of Halozyme, Dr. Helen Torley, highlighted that Daly would serve as an important resource, in the commercialization of the company’s PEGPH20 drug. She also expressed her pleasure at having Daly on board.
Before moving to Halozyme, Mr. Daly was the EVP at Incyte Corporation, from 2012 to 2015. He also has prior experience working with Amgen, as Senior VP of North America commercial operations and global marketing and commercial development. Furthermore, Daly is also known to have started his career at GSK, where he held multiple positions, with varying responsibilities.
Halozyme is also expected to present at the 36th Annual Cowen & Company Healthcare conference, in Boston, on March 9. Added to this, the company has also announced that it would be present at the Barclays Capital Global Healthcare Conference, in Miami, on March 15. HALO would be represented by CFO, Laurie Stelzer, at both conferences.
The company had also filed its 4Q2015 financial results, reporting net earnings of $4.32 million. HALO also reported the widening of its gross-margins from 79.76% to 83.86%, on a year-over-year basis. As a result, the company reported an EPS of $0.03 for the quarter, up by $0.07 as compared to the preceding year. Analysts have stated that the earnings growth of the company is average, as compared to its peer group. This indicates that Halozyme has control over its market share. However, the earnings growth has mostly been influenced by exercising cost controls. Added to this, the revenues have also been affected by several one-time sales, during the quarter. The revenues for the 4Q2014 were 30.38 million, compared to $52.23 million during 4Q2015.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) lost 0.21% of its share value, during the March 7 session, to reach a close at $9.57, after having a trade volume of 2.53 million.